Ftse Mib
34.817,76
0,94%
DAX
18.685,38
1,09%
S&P 500
5.300,05
0,43%
NASDAQ
16.872,87
0,82%
Bitcoin
70.101,36
3,49%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BioCryst Pharmaceuticals Inc (BCRX) BioCryst Pharmaceuticals Inc (BCRX) Notizie

BCRX

BioCryst Pharmaceuticals (BCRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCRX
DataOraFonteTitoloSimboloCompagnia
02/06/202410:00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) TreatmentNASDAQ:BCRXBioCryst Pharmaceuticals Inc
31/05/202422:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/05/202413:00GlobeNewswire Inc.BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical ImmunologyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
13/05/202413:00GlobeNewswire Inc.ORLADEYO® (berotralstat) Approved in MexicoNASDAQ:BCRXBioCryst Pharmaceuticals Inc
09/05/202413:00GlobeNewswire Inc.BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
07/05/202422:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
07/05/202413:00GlobeNewswire Inc.BioCryst to Present at Upcoming Investor ConferencesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/05/202413:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BCRXBioCryst Pharmaceuticals Inc
06/05/202413:00GlobeNewswire Inc.BioCryst Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/05/202413:00GlobeNewswire Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
22/04/202413:00GlobeNewswire Inc.BioCryst to Report First Quarter 2024 Financial Results on May 6NASDAQ:BCRXBioCryst Pharmaceuticals Inc
17/04/202410:30GlobeNewswire Inc.BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory AgencyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
27/02/202423:05Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:BCRXBioCryst Pharmaceuticals Inc
26/02/202413:00GlobeNewswire Inc.BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key MilestonesNASDAQ:BCRXBioCryst Pharmaceuticals Inc
26/02/202411:57IH Market NewsU.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices RetreatNASDAQ:BCRXBioCryst Pharmaceuticals Inc
23/02/202413:00GlobeNewswire Inc.BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) TreatmentNASDAQ:BCRXBioCryst Pharmaceuticals Inc
19/02/202413:54GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in ItalyNASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/02/202422:21Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BCRXBioCryst Pharmaceuticals Inc
14/02/202415:02Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BCRXBioCryst Pharmaceuticals Inc
12/02/202413:00GlobeNewswire Inc.BioCryst to Report Fourth Quarter 2023 Financial Results on February 26NASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/02/202413:00GlobeNewswire Inc.BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual MeetingNASDAQ:BCRXBioCryst Pharmaceuticals Inc
05/01/202422:01GlobeNewswire Inc.BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to ProfitabilityNASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/01/202413:00GlobeNewswire Inc.BioCryst to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BCRXBioCryst Pharmaceuticals Inc
19/12/202313:00GlobeNewswire Inc.BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
29/11/202313:00GlobeNewswire Inc.BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in ArgentinaNASDAQ:BCRXBioCryst Pharmaceuticals Inc
21/11/202313:00GlobeNewswire Inc.BioCryst Launches ORLADEYO® (berotralstat) in SpainNASDAQ:BCRXBioCryst Pharmaceuticals Inc
10/11/202313:00GlobeNewswire Inc.BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)NASDAQ:BCRXBioCryst Pharmaceuticals Inc
08/11/202322:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/11/202317:03GlobeNewswire Inc.BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 MonthsNASDAQ:BCRXBioCryst Pharmaceuticals Inc
03/11/202317:00GlobeNewswire Inc.BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®NASDAQ:BCRXBioCryst Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BCRX

La tua Cronologia

LSE
RIC
Richoux
LSE
62AB
Inter-amer.40
BIT
F25586
Vontobel Financial Produ...
EU
SNCBT
Societe Nationale SNCF S...
EU
SDGPR
Societe du Grand Paris D...
USOTC
MBGAF
Mercedes Benz (PK)
TSXV
PED.H
Pedro Resources
NEO
ZTL
BMO Long Term US Treasur...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network